Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|December 10, 2018
FDA Approves Celltrion and Teva’s Biosimilar to Rituxan
Author(s)Pharmaceutical Technology Editors
FDA has approved Truxima (rituximab-abbs), a biosimilar to Roche’s anti-cancer biologic, Rituxan (rituximab).
Advertisement
Celltrion and Teva Pharmaceutical Industries announced on Nov. 29, 2018 that FDA approved Truxima (rituximab-abbs), a biosimilar referencing Roche’s anti-cancer biologic, Rituxan (rituximab). Rituxan is Roches’ top-selling drug with
According to Celltrion, Truxima is the first rituximab biosimilar to be approved in the United States. The drug was approved for three indications: as a single agent to treat relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non–Hodgkin’s lymphoma (NHL); in combination with chemotherapy for previously untreated follicular, CD20-positive, B-cell NHL and as single-agent maintenance therapy for the same condition in patients achieving a complete or partial response to a rituximab product; and as a single-agent for treating non-progressing, low-grade, CD20-positive, B-cell NHL.
“Truxima is the very first rituximab biosimilar to be approved in the United States for three non-Hodgkin’s lymphoma indications and may help provide greater accessibility for patients,” said Woosung Kee, CEO of Celltrion, in a company press release.
Celltrion and Teva entered into an exclusive partnership in October 2016 to commercialize Truxima in the US and Canada. The two companies have reached a settlement agreement with Genentech, a Roche company, including entry terms. The terms and conditions of the agreement were not disclosed.
Source:
Advertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
5